8-K: NewAmsterdam Pharma's Obicetrapib Shows Significant Reductions in Alzheimer's Biomarkers in BROADWAY Trial

NewAmsterdam Pharma announced positive full data from a prespecified Alzheimer's disease biomarker analysis within its Phase 3 BROADWAY clinical trial, demonstrating statistically significant reductions in key AD pathology markers, particularly in high-risk ApoE4 carriers.

Summary

• NewAmsterdam Pharma presented full data from a prespecified Alzheimer's disease (AD) biomarker analysis from its Phase 3 BROADWAY clinical trial.
• The analysis evaluated the effect of obicetrapib on plasma biomarkers of AD in 1,515 patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) whose ApoE status was determined, including 367 ApoE4 carriers.
• Treatment with obicetrapib 10 mg daily for 12 months resulted in statistically significant lower absolute changes in plasma p-tau217, a key biomarker of AD pathology.
• In the full analysis set (n=1,515), p-tau217 showed a mean reduction of 2.99% (p=0.0019).
• Among ApoE4 carriers (n=367), p-tau217 decreased by 5.74% (p=0.0215).
• For ApoE4/E4 carriers, the highest risk category for AD (n=29), obicetrapib reduced p-tau217 levels by 20.48% (p=0.010).
• Favorable trends were also observed across additional AD biomarkers, including neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), p-tau181, and the A42/40 ratio, with the greatest effects in ApoE4/E4 carriers.
• Obicetrapib was observed to be well-tolerated in the overall BROADWAY study population, with safety results comparable to placebo.
• The BROADWAY trial was primarily designed to evaluate LDL-C lowering efficacy of obicetrapib, which showed a 33% reduction in LDL-C at 84 days.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial results for obicetrapib's impact on Alzheimer's disease biomarkers, especially in high-risk populations, with statistically significant reductions and a favorable safety profile. This represents a significant potential expansion of the drug's therapeutic profile beyond its primary cardiovascular indication, suggesting a strong future outlook and potential for addressing a major unmet medical need.

Positives

• Obicetrapib significantly reduced plasma p-tau217, a key Alzheimer's disease biomarker, in the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215).
• A substantial 20.48% reduction in p-tau217 was observed in ApoE4/E4 carriers (p=0.010), who are at the highest genetic risk for Alzheimer's disease.
• Favorable trends were seen across multiple other neurodegeneration biomarkers (NFL, GFAP, p-tau181, A42/40 ratio), particularly in ApoE4/E4 carriers.
• The safety profile of obicetrapib was comparable to placebo in the broader BROADWAY study population, indicating good tolerability.
• These results build on obicetrapib's established cardiometabolic profile, including significant LDL-C lowering benefits, suggesting a potential dual benefit for cardiovascular and neurodegenerative risks.

Negatives

• The Alzheimer's disease biomarker analysis was based on a subset of patients from the BROADWAY trial and was not controlled for baseline differences between the treatment and placebo populations for this specific AD analysis.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions could impact operations.
• Uncertainty regarding the approval of obicetrapib and the timing of expected regulatory and business milestones.
• Results from the AD analysis and other early studies may not be indicative of the results of later clinical trials.
• Projections regarding clinical outcomes may not reflect actual results in future clinical trials or clinical use of obicetrapib, if approved.
• Potential for varying interpretations of the results of the AD analysis.
• The impact of competitive product candidates could affect market position.
• Uncertainty regarding outcomes of ongoing clinical trials, particularly concerning regulatory review and potential approval for obicetrapib.
• Risks associated with efforts to commercialize obicetrapib.
• Ability to negotiate and enter into definitive agreements on favorable terms, if at all.
• Intellectual property related claims could arise.
• Ability to attract and retain qualified personnel is crucial for continued operations.
• Ability to continue to source raw materials for obicetrapib and manufacture the final product.

Future Outlook

The company plans to discuss these positive Alzheimer's disease biomarker results with regulatory authorities to determine potential next steps for obicetrapib. The findings suggest obicetrapib may offer a unique opportunity to reduce both neurodegenerative and heart disease risks, building on its established LDL-C lowering benefits.

Management Comments

• Michael Davidson, M.D., Chief Executive Officer: "Obicetrapib, our investigational once-daily oral therapy, shows promise by significantly slowing the progression of, and in some instances decreasing, plasma levels of p-tau217, a key Alzheimers biomarker, in this analysis. This is especially important in ApoE4 gene carriers—a group that represents over a quarter of the population and faces a heightened risk for this disease. Combined with its LDL-C lowering benefits observed in multiple clinical trials, obicetrapib may offer a unique opportunity to reduce both neurodegenerative and heart disease risks."
• Philip Scheltens, M.D., Ph.D., Professor Emeritus at Amsterdam UMC: "With more than 25% of the population carrying one or two copies of ApoE4 and no approved preventative therapies, interventions that can slow AD associated biomarker progression may offer a promising path toward delaying or modifying disease onset and progression in this high-risk group."
• John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer: "Obicetrapibs ability to reduce not only p-tau217 in ApoE4 carriers, a well-characterized and defined group, but also multiple additional important AD biomarkers would add a compelling new dimension to its therapeutic profile. Coupled with effects on LDL-C, small dense LDL particles, Lp(a), and metabolic biomarkers observed in multiple clinical trials, these data highlight obicetrapibs potential to address the converging pathways of cardiovascular and neurovascular disease with a single, oral therapy."

Industry Context

Alzheimer's disease remains a devastating global health challenge with no effective preventive treatments currently available. The findings for obicetrapib are significant as they suggest a potential novel, upstream approach to Alzheimer's prevention, particularly in ApoE4 carriers who represent over 25% of the population and face a heightened risk. This announcement links lipid biology and cardiometabolic medicine to neurodegeneration, highlighting the potential for a single oral therapy to address converging pathways of cardiovascular and neurovascular disease, a unique proposition in the current therapeutic landscape.

Comparison to Industry Standards

• p-tau217 is recognized as one of the first biomarkers to provide evidence of neurodegeneration, with increases potentially occurring more than 20 years before cognitive impairment onset.
• Plasma p-tau217 has demonstrated significantly higher accuracy in assessing AD compared to alternative plasmaor MRI-based analyses, and its performance is reported to not significantly differ from key CSFor PET-based measures, positioning it as a highly reliable biomarker.
• NFL and GFAP biomarkers are also considered predictive of neurodegeneration, and elevated levels are associated with AD progression and pathology, reinforcing the comprehensive positive biomarker profile observed.
• ApoE4 is the strongest genetic risk factor for late-onset AD, with its carriers exhibiting increased risk for AD and cardiovascular disease, making the observed effects in this subgroup particularly impactful given the lack of approved preventative therapies for this high-risk population.

Stakeholder Impact

• Shareholders: Positive clinical trial results, especially in a new therapeutic area like Alzheimer's, could significantly increase the company's valuation and future revenue potential, leading to increased share price.
• Patients (with ASCVD/HeFH and/or at risk for AD): Obicetrapib could offer a novel, well-tolerated oral therapy that not only addresses high LDL-C but also potentially slows the progression of Alzheimer's disease, particularly for those with the ApoE4 genetic risk factor, improving patient outcomes and quality of life.
• Healthcare Providers: The drug could provide a new therapeutic option for managing both cardiovascular risk and potentially neurodegenerative risk, simplifying treatment regimens for patients with co-morbidities.
• Regulatory Authorities: The company's intention to discuss these results with regulatory bodies indicates potential for future submissions and approvals for an expanded indication, which could influence public health guidelines.

Next Steps

• Discuss the results of the Alzheimer's disease biomarker analysis with regulatory authorities to determine potential next steps.
• Continue with the ongoing Phase 3 PREVAIL cardiovascular outcomes trial, which completed enrollment of over 9,500 patients in April 2024.

Key Dates

Recommendation

The filing reveals highly significant and positive clinical data for obicetrapib in a new, high-impact therapeutic area (Alzheimer's disease biomarkers), particularly for high-risk ApoE4 carriers. This expands the drug's potential market significantly beyond its primary cardiovascular indication. The statistically significant reductions in key AD biomarkers, coupled with a favorable safety profile and the drug's existing LDL-C lowering benefits, suggest a compelling and differentiated therapeutic profile. This strong clinical validation in a disease with high unmet need positions the company for substantial future growth and potential regulatory success, making it a strong buy for long-term investors.

Keywords

Obicetrapib, Alzheimer's Disease, AD Biomarkers, p-tau217, ApoE4, BROADWAY Trial, Clinical Trial Results, Neurodegeneration, Cardiovascular Disease, CETP Inhibitor, LDL-C, Biopharmaceutical, Phase 3, Drug Development